Gene · 2280
FKBP1A: FKBP prolyl isomerase 1A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. FKBP1A: FKBP prolyl isomerase 1A. Genes, record 2280. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2280
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P62942 | Peptidyl-prolyl cis-trans isomerase FKBP1A | 108 | 113 | Ensembl, GeneID, HGNC |
Source UniProt
Patents251
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026127113 A | 2026-06-18 | 9 | P62942 | Espacenet |
| US 12624353 B2 | 2026-05-12 | 488 | P62942 | Espacenet |
| US 12624353 B2 | 2026-05-12 | 491 | P62942 | Espacenet |
| US 12624354 B2 | 2026-05-12 | 488 | P62942 | Espacenet |
| US 12624354 B2 | 2026-05-12 | 491 | P62942 | Espacenet |
| JP 2026062659 A | 2026-04-10 | 488 | P62942 | Espacenet |
| JP 2026062659 A | 2026-04-10 | 491 | P62942 | Espacenet |
| US 12570972 B2 | 2026-03-10 | 488 | P62942 | Espacenet |
| US 12570972 B2 | 2026-03-10 | 491 | P62942 | Espacenet |
| US 12544448 B2 | 2026-02-10 | 3 | P62942 | Espacenet |
1 to 10 of 251
See all 251 patentsDrugs8
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| EVEROLIMUS | CHEMBL1908360 | FK506-binding protein 1A inhibitor | INHIBITOR | ChEMBL |
| OLOCROLIMUS | CHEMBL3545142 | FK506-binding protein 1A inhibitor | INHIBITOR | ChEMBL |
| PIMECROLIMUS | CHEMBL1200686 | FK506-binding protein 1A inhibitor | INHIBITOR | ChEMBL |
| SIROLIMUS | CHEMBL413 | FK506-binding protein 1A inhibitor | INHIBITOR | ChEMBL |
| TACROLIMUS | CHEMBL3989887 | FK506-binding protein 1A inhibitor | INHIBITOR | ChEMBL |
| TACROLIMUS ANHYDROUS | CHEMBL269732 | FK506-binding protein 1A inhibitor | INHIBITOR | ChEMBL |
| TEMSIROLIMUS | CHEMBL1201182 | FK506-binding protein 1A inhibitor | INHIBITOR | ChEMBL |
| ZOTAROLIMUS | CHEMBL219410 | FK506-binding protein 1A inhibitor | INHIBITOR | ChEMBL |
Trials1,687
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07581704 | SIROLIMUS | PHASE1 | ClinicalTrials.gov | |
| NCT07566377 | TACROLIMUS | PHASE2 | ClinicalTrials.gov | |
| NCT07552077 | SIROLIMUS | PHASE2 | ClinicalTrials.gov | |
| NCT07548983 | TACROLIMUS | PHASE1 | ClinicalTrials.gov | |
| NCT07532330 | TACROLIMUS | ClinicalTrials.gov | ||
| NCT07522801 | EVEROLIMUS | PHASE2 | ClinicalTrials.gov | |
| NCT07519174 | TACROLIMUS | ClinicalTrials.gov | ||
| NCT07519005 | TACROLIMUS | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07518277 | SIROLIMUS | ClinicalTrials.gov | ||
| NCT07477548 | EVEROLIMUS | PHASE2 | ClinicalTrials.gov |
1 to 10 of 1,687
See all 1,687 trialsNIH grants1,367
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | FKBP1A papers | Newest fiscal year |
|---|---|---|---|
| P30CA014089 | University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG) | 8 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 6 | 2025 |
| R01ES014901 | Molecular and Cellular Basis of PCB Developmental Neurotoxicity | 6 | 2025 |
| R01HL140934 | Exploring the Molecular Physiology of Atrial Fibrillation | 6 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 5 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| R01EY026635 | Protein-polymer nanomedicine for Sjogren's Syndrome | 5 | 2025 |
| R25NS076445 | Summer Program for Undergraduate Rising Stars (SPURS), a Columbia University biomedical sciences pipeline program | 5 | 2025 |
| P30CA082103 | Cancer Center Support Grant | 4 | 2025 |
| P50CA126752 | SPORE in Lymphoma | 4 | 2025 |
1 to 10 of 1,367Source NIH's project files
See all 1,367 nih grantsPapers1,820
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PSGS-Drug: Generation-Time Dual-Pocket Guidance for Non-Symmetric Dual-Target Molecular Design. | J Chem Inf Model | 2026 | 42573395 | PubTator, text mining | PubMed |
| Next-generation precision medicine for mood disorders: reproducible blood biomarkers enable objective diagnostics, subtyping, and targeted therapeutics. | Mol Psychiatry | 2026 | 42547801 | PubTator, text mining | PubMed |
| Mechanisms and therapeutic targets in distant metastasis of lung adenocarcinoma. | Signal Transduct Target Ther | 2026 | 42493498 | PubTator, text mining | PubMed |
| Engineering CAR T Cells for Hepatocellular Carcinoma Recurrence after Liver Transplantation. | bioRxiv | 2026 | 42427600 | PubTator, text mining | PubMed |
| FKBP52 in cancer biology and therapy: molecular mechanisms, signalling networks, and drug targeting of the FKBP protein family. | Biochem Pharmacol | 2026 | 42114681 | PubTator, text mining | PubMed |
| HLA-A*11:01 and HLA-C*03 Binding to FKBP1A Influences the Efficacy of Tacrolimus in Myasthenia Gravis Subgroups. | HLA | 2026 | 41925081 | PubTator, text mining | PubMed |
| Identification of a Calcium-Related Prognostic Signature and Validation of CACNA1B as a Driver of Metastasis in Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2026 | 41909196 | PubTator, text mining | PubMed |
| Blood-based epigenetic biomarkers in rheumatoid arthritis: current knowledge and future perspectives. | Front Immunol | 2026 | 41798917 | PubTator, text mining | PubMed |
| Molecular mechanisms in podocytopathies: finding suitable targets for a new era of glomerular gene therapy. | Clin Kidney J | 2026 | 41788620 | PubTator, text mining | PubMed |
| Distinct Proteomic Signatures Driving Progression of Sarcopenia: A Longitudinal Multicohort Study. | J Cachexia Sarcopenia Muscle | 2026 | 41782349 | PubTator, text mining | PubMed |
1 to 10 of 1,820
See all 1,820 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2280
GET https://conductscience.org/api/genes/v1/2280/patents?page=2